NCT06679816View on ClinicalTrials.gov

Hydrocortisone in Hormone Replacement Therapy for Large Pituitary Neuroendocrine Tumors

PHASE4RecruitingINTERVENTIONAL
Enrollment

882

Participants

Timeline

Start Date

December 4, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions
Pituitary AdenomaPituitary Neuroendocrine Tumor
Interventions
DRUG

Hormone replacement therapy

Perioperative Hydrocortisone Reduction Therapy

DRUG

Placebo

Perioperative placebo Reduction Therapy

Trial Locations (1)

100070

RECRUITING

Beijing, Beijing Tiantan Hospital,Capital Medical University, Beijing

All Listed Sponsors
lead

Beijing Tiantan Hospital

OTHER

NCT06679816 - Hydrocortisone in Hormone Replacement Therapy for Large Pituitary Neuroendocrine Tumors | Biotech Hunter | Biotech Hunter